IDH status is prognostic for patient outcome, with the presence of IDH mutations being associated with a more favourable prognosis than IDH wild-type tumours; patients with IDH wild-type tumours have a median overall survival of 14 months compared to IDH mutant with 43 months (4). The gene discussed is IDH1; the disease is neoplasm.